Windtree Therapeutics Inc
WINT
WINT was delisted on the 4th of May, 2017.
0 hedge funds and large institutions have $0 invested in Windtree Therapeutics Inc in 2017 Q4 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 3 closing their positions.
100% less funds holding
Funds holding: 3 → 0 (-3)
100% less capital invested
Capital invested by funds: $41K → $0 (-$41K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$37K |
| 2 |
DY
Dowling & Yahnke
San Diego,
California
|
-$4K |
| 3 |
MPWT
MassMutual Private Wealth & Trust
Windsor,
Connecticut
|
-$4 |
WINT Hedge Fund Activity: Q4 2017 in Review
0 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Windtree Therapeutics Inc (WINT) for Q4 2017, worth a combined $0 — down 100% from $41K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of WINT and 0 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Panagora Asset Management, exiting entirely with an estimated $37K sold.
- 0 institutional investors held Windtree Therapeutics Inc (WINT) as of Q4 2017, down from 3 in Q3 2017.
- Funds reported $0 of Windtree Therapeutics Inc stock for Q4 2017, down 100% quarter-over-quarter.
- 0 funds opened new Windtree Therapeutics Inc positions in Q4 2017 and 3 closed out, a net change of -3 holders.
- The largest Windtree Therapeutics Inc seller in Q4 2017 was Panagora Asset Management, an estimated $37K sold.
Based on aggregated 13F filings for Q4 2017.